Resistance mutation info of drug
Drug General Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug ID | D0Q5NX | ||||||||||
Drug Name | Lenalidomide | ||||||||||
Synonyms | Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator) | ||||||||||
Drug Type | Small molecular drug | ||||||||||
Therapeutic Class | Anticancer Agents | ||||||||||
Company | Celgene Corporation | ||||||||||
Structure | |||||||||||
Drug Resistance Mutations | |||||||||||
Target Name | Protein cereblon (CRBN) | Target Info | |||||||||
Gene Name | CRBN | ||||||||||
Uniprot ID | CRBN_HUMAN | ||||||||||
Species | Homo sapiens | ||||||||||
Reference Sequence |
MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYL GADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTF AVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQA KVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSW PRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLK IGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETL TVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRS ALLPTIPDTEDEISPDKVILCL [Homo sapiens] |
||||||||||
Targeted Disease | Myeloma | ||||||||||
Drug Resistance Mutations |
|
||||||||||
|
|||||||||||
References | |||||||||||
REF 1 | Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013 Jun;161(5):748-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.